Paul Tudor Jones’s CRISPR Therapeutics CRSP Stock Holding History

Paul Tudor Jones’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$873K	Sell	16,000 -5,800	-27%	-$306K	﹤0.01%	2508
2026 Q1	$1.04M	Buy	21,800 +800	+4%	+$42.2K	﹤0.01%	2351
2025 Q4	$1.1M	Sell	21,000 -6,100	-23%	-$365K	﹤0.01%	2200
2025 Q3	$1.76M	Sell	27,100 -16,900	-38%	-$970K	﹤0.01%	1885
2025 Q2	$2.14M	Sell	44,000 -4,600	-9%	-$178K	﹤0.01%	1622
2025 Q1	$1.65M	Buy	48,600 +43,200	+800%	+$1.83M	0.01%	1476
2024 Q4	$213K	Buy	+5,400	New	+$255K	﹤0.01%	2802
2024 Q1	–	Sell	-17,100	Closed	-$1.07M	–	2313
2023 Q4	$1.07M	Buy	+17,100	New	+$945K	0.01%	1404

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paul Tudor Jones's CRSP Position: Q2 2026 in Review

Paul Tudor Jones reduced its CRISPR Therapeutics (CRSP) stake by 2.1% in Q2 2026, selling an estimated $47.4K and leaving 42,512 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

Paul Tudor Jones first reported a position in CRSP in Q1 2018 and has held it in 21 quarters since. The position peaked at $2.42M in Q4 2020. 520 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Paul Tudor Jones held 42,512 shares of CRISPR Therapeutics worth $2.32M as of Q2 2026.
Paul Tudor Jones sold 899 CRISPR Therapeutics shares in Q2 2026, an estimated $47.4K.
CRISPR Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1845 holding.
Paul Tudor Jones first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 21 quarters since.
Paul Tudor Jones's CRISPR Therapeutics position peaked at $2.42M in Q4 2020.
520 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.